Consumer Lawyers

Jan 11 2012 Heart attack risk seen with clot drug Pradaxa

In Uncategorized on January 13, 2012 at 3:51 am

Not a recall, but news for mid week:

Boehringer Ingelheim’s Pradaxa blood clot preventer has been associated with a slightly higher risk of heart attack or acute coronary syndrome, according to results of a meta-analysis of several studies reported in a major medical journal.

The relative increase in risk to comparative medicines was found to range from 27 to 33 percent, however the absolute risk increase for suffering a heart attack was only 0.27 percent, the authors of the meta-analysis said in the study published on Monday in the Archives of Internal Medicine online edition.

Pradaxa, known chemically as dabigatran, is approved in the United States for stroke prevention in patients suffering from an irregular heart beat known as atrial fibrillation, and in Europe to prevent strokes caused by blood clots in patients who have undergone hip and knee replacements.

 

http://www.reuters.com/article/2012/01/09/us-heartattack-pradaxa-idUSTRE8082CX20120109

Advertisements

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: